Bayer to Highlight New Data for KERENDIA® (finerenone) at Heart Failure Society of America (HFSA) Annual Scientific Meeting 2025

About this update from Bayer Ag

[{"type":"list","items":[{"val":[{"type":"text","content":"Data to be presented include two subgroup analyses from the pivotal Phase III FINEARTS-HF trial, which assessed the safety and efficacy of finerenone versus placebo in heart failure (HF) patients with left ventricular ejection fraction (LVEF) ≥40%. These analyses explored potential treatment effects in patients across a range of heart failure duration or who have high medication burden.","length":389,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Additionally, retrospective real-world data will be presented on guideline-directed medical therapy treatment patterns in the U.S. for newly diagnosed HF, stratified by LVEF, as well as on clinical outcomes after onset of HF with LVEF ≥40%.","length":240,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":629,"olType":false},{"type":"text","content":"WHIPPANY, N.J., September 25, 2025--(BUSINESS WIRE)--Bayer announced today that data from across the KERENDIA® (finerenone) comprehensive clinical trial program will be presented at the Heart Failure Society of America (HFSA)’s Annual Scientific Meeting in Minneapolis, Minnesota, September 26-29, 2025.","length":303,"tagName":"p"},{"type":"text","content":"In July 2025, the U.S. Food and Drug Administration (FDA) approved a new indication for KERENDIA to treat adult patients with heart failure (HF) with left ventricular ejection fraction (LVEF) ≥40%, following the agency’s Priority Review of its supplemental New Drug Application (sNDA).1 Since July 2021, KERENDIA has been approved to reduce the risk of CV death, hospitalization for HF, non-fatal myocardial infarction (MI), sustained estimated glomerular filtration rate (eGFR) decline, and end-stage kidney disease in adult patients with CKD associated with T2D.1","length":565,"tagName":"p"},{"type":"text","content":"Data from Bayer at HFSA include:","length":32,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Finerenone, Polypharmacy, And Clinical Outcomes In Heart Failure: Insight From The FINEARTS-HF Trial","length":100,"tagName":"p","attribs":{}},{"type":"list","items":[{"val":[{"type":"text","content":"Board and Poster: 134; September 27, 7:45 – 8:15 AM CDT","length":55,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":55,"olType":false}]},{"val":[{"type":"text","conte...

More updates from Bayer Ag